Cardiovascular and Metabolic Comorbidities in Patients with Plaque-Type Psoriasis Never Treated with Systemic Antipsoriatic Drugs: a Case-Control Study
Journal
Serbian Journal of Dermatology and Venereology
Date Issued
2013-06-01
Author(s)
Neloska, Lenche
Gocev, Gjeorgji
Abstract
Previous studies have shown a higher prevalence of cardiometabolic diseases among patients with psoriasis compared to non-psoriatics. However, little attention has been paid to the effects of systemic antipsoriatic drugs. The aim of this
study was to investigate the association between psoriasis and these comorbidities, comparing untreated patients with
psoriasis and population-based control non-psoriatic patients.
A hospital-based case-control study included 122 patients with plaque-type psoriasis and 122 age- and gender-matched
controls. Patients who ever received systemic antipsoriatic drugs were excluded.
There were no significant differences between psoriatic patients and controls regarding the prevalence of hypertension
(p=0.311), coronary heart disease (p=0.480), diabetes (p=0.641), myocardial infarction (p=0.71), stroke (2.4% vs.
2.4%, p=1.00) and metabolic syndrome (p=0.764). The prevalence of hypertriglyceridemia in patients with psoriasis
and controls was 41.8% and 28.7%, respectively (OR 1.78, 95% CI 1.04-3.04, p=0.032). Furthermore, significant
differences were observed in mean triglyceride levels (p=0.013). Smoking was significantly more often reported in
psoriatic patients compared to controls. Patients with psoriasis also had a higher mean BMI (26.24, SD 4.42) compared
with controls (24.73, SD 3.86), p=0.005. Psoriasis showed a statistically significant association with BMI obesity
classification [2(4)=11.560, p=0.02].
The prevalence of cardiovascular and metabolic comorbidities was not significantly higher in patients with plaquetype psoriasis who were never treated with systemic antipsoriatic drugs, compared to population-based non-psoriatic
controls. Our data suggest that systemic antipsoriatic drugs may play an important role in the development of these
comorbidities. However, this study confirms that untreated psoriasis patients have three major modifiable increased
cardiovascular risk factors, such as smoking, obesity and hypertriglyceridemia.
study was to investigate the association between psoriasis and these comorbidities, comparing untreated patients with
psoriasis and population-based control non-psoriatic patients.
A hospital-based case-control study included 122 patients with plaque-type psoriasis and 122 age- and gender-matched
controls. Patients who ever received systemic antipsoriatic drugs were excluded.
There were no significant differences between psoriatic patients and controls regarding the prevalence of hypertension
(p=0.311), coronary heart disease (p=0.480), diabetes (p=0.641), myocardial infarction (p=0.71), stroke (2.4% vs.
2.4%, p=1.00) and metabolic syndrome (p=0.764). The prevalence of hypertriglyceridemia in patients with psoriasis
and controls was 41.8% and 28.7%, respectively (OR 1.78, 95% CI 1.04-3.04, p=0.032). Furthermore, significant
differences were observed in mean triglyceride levels (p=0.013). Smoking was significantly more often reported in
psoriatic patients compared to controls. Patients with psoriasis also had a higher mean BMI (26.24, SD 4.42) compared
with controls (24.73, SD 3.86), p=0.005. Psoriasis showed a statistically significant association with BMI obesity
classification [2(4)=11.560, p=0.02].
The prevalence of cardiovascular and metabolic comorbidities was not significantly higher in patients with plaquetype psoriasis who were never treated with systemic antipsoriatic drugs, compared to population-based non-psoriatic
controls. Our data suggest that systemic antipsoriatic drugs may play an important role in the development of these
comorbidities. However, this study confirms that untreated psoriasis patients have three major modifiable increased
cardiovascular risk factors, such as smoking, obesity and hypertriglyceridemia.
Subjects
File(s)![Thumbnail Image]()
Loading...
Name
Cardiovascular_and_Metabolic_Comorbidities_in_Pati.pdf
Size
299.25 KB
Format
Adobe PDF
Checksum
(MD5):ade0a422a75d36d0e2a658383421a84e